Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. AKBA
AKBA logo

AKBA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Akebia Therapeutics Inc (AKBA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.360
1 Day change
4.62%
52 Week Range
4.080
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

AKBA is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is showing short-term bullish momentum, but it is overbought and lacks strong fundamental, news, insider, or institutional catalysts. With no AI Stock Picker or SwingMax signal, I would not classify this as an attractive immediate entry.

Technical Analysis

The trend is mildly bullish in the very short term: MACD histogram is positive and expanding, and price is near the first resistance at 1.248 after closing at 1.235. However, RSI_6 is 80.286, which is strongly overbought, suggesting the move has likely run ahead of itself. Moving averages are converging, which points to an unclear medium-term trend rather than a strong sustained breakout. Support is at 1.135 and 1.023, while resistance is at 1.248 and 1.317. Overall, momentum is positive but stretched.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish by positioning, with a low open interest put-call ratio of 0.2 and zero put volume reported versus 39 call volume. That said, option activity is very light, and implied volatility is extremely high at 538.54 with IV percentile at 100, which suggests the options market is pricing in large uncertainty. The flow looks call-biased, but not strong enough to override the weak broader setup.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
8

Positive Catalysts

  • ["MACD histogram is positive and expanding, indicating upward momentum", "Options positioning is call-biased with low put-call ratios", "Price is trading near short-term resistance, showing near-term strength", "Similar candlestick pattern analysis suggests modest upside probabilities over 1 day, 1 week, and 1 month"]

Neutral/Negative Catalysts

  • ["RSI_6 at 80.286 indicates the stock is overbought", "No news in the recent week, so there are no fresh event-driven catalysts", "No significant hedge fund or insider buying trend", "No recent congress trading data", "No AI Stock Picker signal and no recent SwingMax buy signal", "Financial snapshot data is unavailable, so there is no visible fundamental confirmation"]

Financial Performance

Latest quarter financial data was not available due to an error in the provided snapshot, so there is no confirmed revenue, earnings, or growth readout to support a long-term buy decision. Because of that, the current case relies mostly on price action and sentiment rather than fundamentals, which is not ideal for a beginner long-term investor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so there is no evidence of a recent upgrade cycle or increasing price targets. Based on the available information, Wall Street sentiment cannot be described as strongly bullish; the pros are limited to technical momentum and call-heavy options activity, while the cons are the absence of news, the lack of fundamental visibility, and the overbought technical state.

Wall Street analysts forecast AKBA stock price to rise
3 Analyst Rating
Wall Street analysts forecast AKBA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.300
sliders
Low
4
Averages
5
High
6
Current: 1.300
sliders
Low
4
Averages
5
High
6
BTIG
Buy
downgrade
$5 -> $4
AI Analysis
2026-02-25
Reason
BTIG
Price Target
$5 -> $4
AI Analysis
2026-02-25
downgrade
Buy
Reason
BTIG lowered the firm's price target on Akebia to $4 from $5 and keeps a Buy rating on the shares. The firm is citing a new US Renal Care protocol related to observed dosing contributed to a decrease in channel inventory of $4.5M-$5.0M, leading to a lower-than-expected Vafseo revenue recognized in Q4 of $5M-$6M, the analyst tells investors in a research note.
Piper Sandler
Allison Bratzel
Overweight
downgrade
$6 -> $4
2026-02-06
Reason
Piper Sandler
Allison Bratzel
Price Target
$6 -> $4
2026-02-06
downgrade
Overweight
Reason
Piper Sandler analyst Allison Bratzel lowered the firm's price target on Akebia to $4 from $6 and keeps an Overweight rating on the shares. Following a number of Q4/FY25 pre-releases in recent weeks and ahead of Q4 reporting, the firm is taking the opportunity to review and adjust its estimates for some of its commercial names, as well as some price targets.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AKBA
Unlock Now

People Also Watch